Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society
- PMID: 31413170
- PMCID: PMC6746206
- DOI: 10.1212/WNL.0000000000008105
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society
Erratum in
-
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.Neurology. 2020 Jan 7;94(1):50. doi: 10.1212/WNL.0000000000008750. Epub 2019 Dec 10. Neurology. 2020. PMID: 31822575 Free PMC article. No abstract available.
Abstract
Objective: To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.
Methods: The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended.
Results: Fifteen Class I-III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency.
Recommendations: The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision-making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.
© 2019 American Academy of Neurology.
Figures
Comment in
-
Guideline update: Pharmacologic prevention of pediatric migraine.J Pediatr. 2020 Jan;216:242-245. doi: 10.1016/j.jpeds.2019.10.075. J Pediatr. 2020. PMID: 31843118 No abstract available.
Similar articles
-
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.Headache. 2019 Sep;59(8):1144-1157. doi: 10.1111/head.13625. Headache. 2019. PMID: 31529477
-
Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.Neurology. 2019 Sep 10;93(11):487-499. doi: 10.1212/WNL.0000000000008095. Epub 2019 Aug 14. Neurology. 2019. PMID: 31413171 Review.
-
Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.Neurology. 2004 Dec 28;63(12):2215-24. doi: 10.1212/01.wnl.0000147332.41993.90. Neurology. 2004. PMID: 15623677 Review.
-
Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.Headache. 2019 Sep;59(8):1158-1173. doi: 10.1111/head.13628. Headache. 2019. PMID: 31529481
-
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.Neurology. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Neurology. 2012. PMID: 22529202 Free PMC article. Review.
Cited by
-
Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine.Toxins (Basel). 2024 May 11;16(5):221. doi: 10.3390/toxins16050221. Toxins (Basel). 2024. PMID: 38787073 Free PMC article.
-
Clinical characterization of pediatric acute confusional migraine: a single-center case series.Acta Neurol Belg. 2024 May 16. doi: 10.1007/s13760-024-02582-1. Online ahead of print. Acta Neurol Belg. 2024. PMID: 38755330
-
Non-Pharmacological Treatments in Paediatric Migraine.J Clin Med. 2024 Feb 23;13(5):1278. doi: 10.3390/jcm13051278. J Clin Med. 2024. PMID: 38592096 Free PMC article. Review.
-
Neuromodulation in Pediatric Migraine using Repetitive Neuromuscular Magnetic Stimulation: A Feasibility Study.Children (Basel). 2023 Oct 30;10(11):1764. doi: 10.3390/children10111764. Children (Basel). 2023. PMID: 38002855 Free PMC article.
-
Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine.Front Neurol. 2023 Sep 27;14:1263535. doi: 10.3389/fneur.2023.1263535. eCollection 2023. Front Neurol. 2023. PMID: 37830088 Free PMC article. Review.
References
-
- Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30:1065–1072. - PubMed
-
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2018;38:1–211. - PubMed
-
- Lopez J, Bechtel KA, Rothrock JF. Pediatric headache [online]. Available at: emedicine.medscape.com/article/2110861-overview. Accessed February 28, 2015.
-
- Hershey AD, Powers SW, Vockell AL, LeCates S, Kabbouche MA, Maynard MK. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology 2001;57:2034–2039. - PubMed
-
- American Academy of Neurology. Clinical Practice Guideline Process Manual, 2011 ed. St. Paul: American Academy of Neurology; 2011.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous